Related Experiment Videos

Brain methylation and epileptogenesis: the case of methionine sulfoximine

Annals of Neurology
|January 1, 1984
PubMed

Insights

L-methionine-dl-sulfoximine (MSO) causes seizures by disrupting brain methylation processes. High S-adenosyl-L-homocysteine levels protect against MSO-induced seizures by inhibiting these reactions.

Area of Science:

  • Neurochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Cerebral methylation reactions are crucial for normal brain function.
  • Convulsant agents can disrupt these vital processes.
  • Understanding the neurochemical basis of seizures is essential for developing treatments.

Purpose of the Study:

  • To review the neurochemical effects of L-methionine-dl-sulfoximine (MSO) on cerebral methylation.
  • To identify endogenous molecules involved in MSO-induced convulsant effects.
  • To explore the role of S-adenosyl-L-homocysteine in MSO-induced seizures.

Main Methods:

  • Review of existing literature on MSO's neurochemical effects.
  • Analysis of endogenous methyl acceptor molecules.
  • Investigation of S-adenosyl-L-homocysteine levels in relation to MSO-induced seizures.

Main Results:

  • MSO's convulsant effects involve endogenous methyl acceptors like histamine, phospholipids, and proteins.
  • High brain S-adenosyl-L-homocysteine levels inhibit methylation and protect against MSO-induced seizures.
  • MSO accelerates methylation-demethylation sequences at sites including the benzodiazepine receptor complex.

Conclusions:

  • MSO disrupts cerebral methylation, leading to seizures.
  • Imbalance in methylation-demethylation sequences, particularly at the benzodiazepine receptor complex, underlies MSO's convulsant action.
  • S-adenosyl-L-homocysteine plays a protective role by inhibiting methylation.

Related Concept Videos